source
- Seven deaths linked to Neurocrine’s Prader-Willi drug Vykat raise safety concernsClinicians have warned that seven patients who received Neurocrine Biosciences' recently approved Prader-Willi syndrome therapy Vykat have died, prompting a new safety alert for the patient communi…
- Definium’s oral LSD candidate DT120 shows strong anxiety reduction in Phase 3 trialDefinium Therapeutics reported that its single‑dose oral LSD candidate DT120 achieved a statistically significant reduction in anxiety symptoms in a Phase 3 study of generalized anxiety disorder. T…